Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Gains from Investment Securities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Gains from Investment Securities for 11 consecutive years, with $205418.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 80.32% to $205418.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $205418.0, a 92.6% decrease, with the full-year FY2025 number at $211618.0, up 44.41% from a year prior.
  • Gains from Investment Securities was $205418.0 for Q4 2025 at Aytu Biopharma, down from $211618.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.6 million in Q2 2024 to a low of -$2.6 million in Q2 2021.
  • A 5-year average of -$60822.1 and a median of $52861.0 in 2022 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 18237.41% in 2024, then tumbled 344.5% in 2025.
  • Aytu Biopharma's Gains from Investment Securities stood at $90731.0 in 2021, then tumbled by 41.74% to $52861.0 in 2022, then soared by 229.17% to $174000.0 in 2023, then soared by 500.0% to $1.0 million in 2024, then tumbled by 80.32% to $205418.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Gains from Investment Securities are $205418.0 (Q4 2025), $211618.0 (Q2 2025), and -$889000.0 (Q1 2025).